Eprodisate

Drug Profile

Eprodisate

Alternative Names: Eprodisate disodium; Eprodisate sodium; Fibrillex; Kiacta; NC-503

Latest Information Update: 28 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BELLUS Health
  • Developer Auven Therapeutics; BELLUS Health
  • Class Alkanes; Anti-inflammatories; Small molecules; Sulfonic acids
  • Mechanism of Action Serum amyloid A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Sarcoidosis
  • Preregistration Submission Withdrawal Amyloid A amyloidosis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 21 Dec 2016 Discontinued - Phase-III for Amyloid A amyloidosis in USA, European Union, Russia, Israel, Peru, Mexico, India, Argentina, Turkey, Brazil, Chile, Egypt, Tunisia, Ukraine, Georgia, Japan (PO)
  • 21 Jan 2016 Auven Therapeutics and Auven Therapeutics complete a phase III trial in Amyloid A amyloidosis in countries worldwide (NCT01215747)
  • 19 May 2015 Eprodisate is still in phase III trials for Amyloid A amyloidosis in the USA, European Union, Argentina, Brazil, Chile, Egypt, Mexico, Israel, India, Peru, Russia, Ukraine, Tunisia and Turkey
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top